Diffusion Pharmaceuticals announced that it has entered into a settlement agreement with LifeSci Special Opportunities Master Fund Ltd., affiliated entities and certain related parties, with respect to, among other things, the membership and composition of the company’s board of directors, before the company’s 2022 Annual Meeting of Stockholders. Under the terms of the agreement, LifeSci Special Opportunities will withdraw its slate of director nominees previously nominated for election and vote in favor of the Board’s recommended nominees at the Annual Meeting. Diffusion has agreed that, in the event it has not completed a transaction resulting from its ongoing strategic review process by July 1, 2023, the company will promptly appoint an individual designated by LifeSci Special Opportunities to the Board, subject to certain conditions.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DFFN:
- Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities
- Diffusion Pharmaceuticals urges shareholders to vote for six board nominees
- Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci’s History of Stockholder Value Destruction and Self-Dealing
- Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
- Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process